Questcor Commits $500,000 to Launch of Questcor Research Fellowship Program
- Ten researchers awarded fellowship grants to further study in neurology,
nephrology and rheumatology -
HAYWARD, Calif., Jan. 22, 2014
HAYWARD, Calif., Jan. 22, 2014 /PRNewswire/ --Questcor Pharmaceuticals, Inc.
(NASDAQ: QCOR) today announced that it has funded independent researchers at
10 institutions for 2014. These investigators represent the first recipients
of the newly-established Questcor Research Fellowship Program, which awards
grants of $50,000 each to selected clinical and basic scientists to help fund
"As a company, we actively support innovative research at academic or
non-profit institutions in the basic sciences, translational research,
clinical research and applied fields," said Steve Cartt, Questcor Chief
Operating Officer. "Our hope is that the research we fund will ultimately
help advance the translation of biomedical science into treatments,
preventions and even cures for human auto-immune and inflammatory diseases."
The Program presently focuses on the fields of nephrology, neurology and
rheumatology. Winning grants were reviewed and selected by an independent
panel of academic experts not affiliated with Questcor.
Dr. Gary Hogge, Vice President of Medical Affairs at Questcor, said the
objective of the program is to provide grants to fellows, junior clinicians,
residents and post-doctoral researchers pursuing a research-oriented career in
neurology, nephrology or rheumatology. Dr. Hogge said, "Research will be
conducted at eligible academic institutions and will address essential
scientific questions related to conditions such as multiple sclerosis,
infantile spasms, glomerular diseases and related disorders, rheumatoid
arthritis, systemic lupus erythematosus, psoriatic arthritis, dermatomyositis,
polymyositis, and ankylosing spondylitis."
The following is a list of the institutions whose researchers are recipients
of grants from the Questcor Research Fellowship Program for 2014:
Hetkoen Institute for Medical Research
Icahn School of Medicine at Mount Sinai
The Ohio State University Office of Sponsored Programs
The Regents of the University of California, San Francisco
The Brigham and Women's Hospital, Inc.
Beth Israel Deaconess Medical Center
University of California, Los Angeles
Rush University Medical Center
According to Dr. Hogge, the fellowships will be funded for one academic year
in the amount of $50,000 per year and may be renewable for a second year
(contingent on progress towards the pre-stated research objectives). The
application process will reopen on April 15, 2014 and close on June 1, 2014.
For more information and eligibility criteria, please visit www.Questcor.com
after February 1, 2014.
About Questcor Pharmaceuticals
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Questcor's specific areas of focus are in the fields
of neurology, nephrology and rheumatology, and the company is currently
supporting research efforts in a variety of conditions having significant
unmet medical need. For more information about Questcor, please visit
SOURCE Questcor Pharmaceuticals, Inc.
Contact: Mark Leonard, 847-651-9682, firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.